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ABSTRACT 
 
Glioblastoma multiforme (GBM) is one of the most common and aggressive human brain 
tumors, accounting for 52% of all primary brain tumors. The median survival for a person 
diagnosed with GBM is 15 months.  GBM originates in glial cells, cells that provide support and 
protection to neurons in the nervous system. The current treatments for glioblastoma include 
surgery and chemotherapy, but prolonged remission is rare with the median time for tumor 
recurrence being about 6.9 months. GBM is currently being studied in human cells and animal 
models, including the fruit fly Drosophila melanogaster. Fly glioblastoma models have been 
developed, but there was no equivalent cell culture model of the glioblastoma in flies. I aimed to 
develop a fly-cell model of glioblastoma. I am generating cell culture line of glial cells by 
expressing an oncogene, RasV12, which is known to be involved in GBM, and by repression of  
tumor suppressors, such as brat.  The human homolog of brat, TRIM3, has been implicated in 
GBM. To date, I have developed one cell line.  To determine if the cell line I generated is of 
glial-cell type, I analyzed the cells using a glial specific cell marker, confirming that the cells 
were indeed glial. The glial cell line that has been developed has the potential to be useful in 
understanding the basic mechanisms of the disease and for testing therapies. 
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INTRODUCTION 
 
Glioblastoma multiforme (GBM) is the most invasive type of glial tumor in which 
malignant cells can rapidly spread to nearby brain tissue.  GBM most commonly originates in the 
cerebral hemispheres of the brain and complete removal of the tumor without damaging vital 
normal brain tissue is impossible due to the dispersal of the malignant cells.  Because of the 
particularly infiltrative and aggressive properties of GBM, current treatments including surgery 
and chemotherapy often provide a higher quality of life for the diagnosed, but do not result in the 
complete removal of cancerous tissue.  GBM typically results in death 15 months after the initial 
diagnosis (AANS - Glioblastoma Multiforme n.d.). According to the National Cancer Institute, 
of the 22,850 American men and women diagnosed with brain or other nervous system cancer in 
2015, 15,320 people have already died (The RAS Problem - National Cancer Institute n.d.). The 
5-year survival rate for GBM is 4% (Tumor Types- National Brain Tumor Society n.d.).  
Drosophila melanogaster is a highly-studied model organism with well-defined genetics. 
Although simpler, the Drosophila central nervous system shares many similarities with that of 
the mammalian system.  There are neurons and glia.  Both the Drosophila glial blood-brain 
barrier and the mammalian endothelial blood-brain barrier protect the nervous system from 
pathogens and regulate the concentrations of solutes and metabolites (Limmer et al. 2014).  In 
addition, the organization of the brain is similar. (McGurk, Berson, and Bonini 2015). In both 
mammals and Drosophila, glial cells are non-neuronal cells responsible for supporting the 
nervous system, including providing nutrients to the neurons and maintaining extracellular ion 
balance. There are three main classes of mammalian glial cells in the central nervous system, 
each with distinct morphologies and roles: oligodendrocytes, microglia, and astrocytes. 
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Likewise, there are three main classes of neuron-associated Drosophila glial cells: astrocytes, 
cortex glia, and ensheathing glia. Together, these three classes share noteworthy molecular and 
functional characteristics with mammalian glial cells (Freeman 2015). Because of these 
similarities, Drosophila is an effective model for studying GBM.   In addition, the fruit fly 
genome (1.2 X 108  base pairs) is simpler than that of the human genome (3.3 X 109 base pairs), 
with about 6,000-11,000 fewer protein-coding genes.  In humans, many of these additional genes 
perform overlapping functions.  The less redundant Drosophila genome is therefore useful for 
loss of function studies in which phenotypes might be seen that are masked in the more complex 
genomes of other animals. 
Drosophila has been an effective in vivo model of gliomas. In mammals, gliomas 
commonly occur when the EGFR and P13K pathways are both activated (Furnari et al. 2007; 
Maher et al. 2001). In flies, the activation of these pathways in embryonic glial cells resulted in 
over-proliferating glial cells.  Upon injection into adults, the cells invaded and grew, forming 
tumors through the activation of a network of oncogenic genes (Read et al. 2009).  
Drosophila is an effective model for studying cancer; the roles of many tumor suppressor 
and oncogene pathways in brain cancer have been studied using a fly model. For example, 
experiments performed in Drosophila provided some of the first evidence of the regulation of 
Ras pathway signaling by the NF1 gene encoding neurofibromin, a protein associated with the 
Neurofibromatosis Type 1 brain cancer in children, characterized by the unchecked growth of 
tissues along nerve cells (Read et al. 2009; Rudrapatna, Cagan, and Das 2012). 
 Drosophila has been used as a whole-animal model for GBM  (Read et al. 2009), but 
there is no corresponding fly cell culture model of glioblastoma.  A fly cell culture model of 
GBM would provide an alternative environment as a useful complement to an in vivo model, in 
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which RNAi screens related to GBM have already been conducted (Read et al. 2013).  A cell line 
provides a large amount of homogenous cells that can be more easily manipulated (Cherbas and 
Gong 2014).  RNA interference (RNAi) in cell culture is a cheap, effective, and simple way to 
silence genes (Caplen et al. 2000; Clemens et al. 2000).  Using a fly-cell culture model of GBM 
in complement to a whole-animal model could help us find novel factors blocking the 
progression of GBM and could lead to the development of new therapies. 
Fly cell lines have some advantages over mammalian cell lines.  They remain alive at 
room temperature and atmospheric levels of CO2, making the handling and imaging of 
Drosophila cell lines much easier (Baum and Cherbas 2008).  
I have developed a glial-specific Drosophila cell line using the Gal4/UAS system, a 
system in which a specific subset of cells (glial cells) can 
be induced to express an oncogene, RasV12.  RasV12 is a 
protein in the Epidermal Growth Factor Receptor Pathway 
with a role in 30% of human cancers, including GBM.  
The Gal4 driver that I used is a well-known glial-specific 
driver, repo-Gal4 (Yuasa et al. 2003).   Shown in Figure 1, 
the repo protein is expressed in the glial nuclei of 
developing Drosophila. 
 
 
 
 
 
Figure 1: anti-Repo antibody staining of 
embryo.  Repo is expressed in the glial 
cells of the nervous system.  Photo 
courtesy of Karla Daniels. 
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MATERIALS AND METHODS 
 
Fly Stocks 
The following gene alleles and transgenes were used: repo-Gal4, UAS-RasV12; UAS-GFP, 
UAS-RasV12, P[attP.w+.attP]JB89B/TM3 (Bateman, Lee, and Wu 2006), UAS-P35, UAS-RasV12, 
UAS-wts dsRNA; UAS-RasV12 ; UAS-wtsdsRNA; tubG80TS; UAS-RasV12. 
Gal4/UAS System 
I utilized the Gal4/UAS system to generate glial cells that express RasV12.  To establish 
the lines, I crossed two transgenic fly lines: the first line expressing the Gal4 gene in glial cells 
and the second line carrying the Upstream Activating Sequence (UAS), to which Gal4 binds, 
upstream of RasV12 or other genes of interest. The Gal4 is expressed only in the glial cells, 
activating transcription of either RasV12 or these genes and leading to the proliferation of glial 
cells in culture (Brand and Perrimon 1993; Simcox et al. 2008).   
Primary culture 
Embryos were collected every 12 hours at room temperature, rinsed from a petri dish and 
collected in a sieve. The embryos were washed using TXN (0.7% NaCl, 0.02% Triton X-100), 
then 50% bleach in water for 3–5 minutes to remove the chorion and surface sterilize the 
embryos. The embryos were washed 6 times with TXN and transferred to a homogenizer 
(Wheaton 5 ml). The embryos were rinsed once in sterile water and once in 2 ml medium 
(Schneider's medium, supplemented with 10% heat-inactivated fetal bovine serum, and 1/100 
dilution of streptomycin penicillin liquid, Invitrogen) and then homogenized in 3 ml medium .  
The cells were pelleted by centrifugation and rinsed with three changes of medium. The cells 
were plated in 12.5 cm2 T-flasks and grown at various termperatures (18-25 ºC). To maintain the 
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primary cultures, the medium (Schneider’s Insect Medium) was changed every 10 days (Simcox 
et al. 2008).   
Passaging  
Confluent cultures were trypsinized and diluted 1/2–1/4. Early passages were often 
difficult to establish and slow to grow to confluence, so were not diluted. The parent culture was 
maintained (with fresh medium) and used to establish multiple first passage cultures before one 
line showed successful continued growth (Simcox et al. 2008). 
Immunohistochemistry  
Cells were grown in 6-well plates for antibody staining. Cells were washed once in 1× 
PBS and fixed for 20 minutes in 4% paraformaldheyde in PBS. Cells were washed in PBS and 
permeablized with PBS+0.2% Triton X-100 (PBTX).  Cells were washed in PBS and blocked in 
PBS with 5% Normal Goat Serum (NGS) for 1 hour and incubated with primary antibody and 
5% NGS, overnight at 4°C. Cells were washed PBS and secondary antibodies (1∶100) were 
added and incubated for 30 mins-1 hour at room temperature. Cells were washed in PBS and 
mounted using VectaShield (Vector Laboratories). Images were captured using a compound 
fluorescence microscope (Simcox et al. 2008).  The following antibodies were used: 8D12 anti-
repo, 22C10, 1D4 anti-Fasciclin II (Hybridoma), anti-HRP. 
Karyotyping  
Cells  at  about  50%  confluence  were  incubated  with  a  final  concentration of   
0.01μg/ml   N-desacetyl-N-methylocolchicine   (KaryoMAX, Gibco) for   3 hours.  Cells   were 
harvested  with  trypsin,  washed  in  Phosphate  buffered  saline  (PBS)  and  resuspended  in  5  
ml 0.075 M KCl and 1.3 mM sodium acetate  (hypotonic solution) for 30 minutes. Four drops of 
fix (3:1 methanol:glacial acetic acid) were added and the cells were centrifuged, resuspended in 
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fix and incubated for 10 minutes.  Cells  were  centrifuged,  resuspended  in  a  small  quantity  
of  fix  and  dropped onto clean slides.  Slides   were   mounted  in   VECTASHIELD   with   
DAPI   (Vector Laboratories)   and approximately 50 mitotic spreads were scored (Manivannan 
et al. 2015). 
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RESULTS AND DISCUSSION 
Primary cultures under the control of repo-Gal4 expressing RasV12 and GFP 
The Gal4 driver that I used is a well-known glial-specific driver, repo-Gal4.  Repo, short 
for reversed polarity, is a homeodomain transcription factor expressed in glial cells and 
important in glial cell differentiation (Yuasa et al. 2003).  To generate a glial cell line, I crossed 
repo-Gal4 to UAS RasV12, UAS-GFP and the progression of a primary culture from the initial 
stages to confluence is shown in Figure 2.  Primary cultures contain many cells and cell types 
initially and are confluent at around 20-30 days.  I was unable to establish continuous cell lines 
using the reporter UAS-RasV12,UAS-GFP. 
 
repo-Gal4; UAS-RasV12; RMCE 
repo-Gal4 was used to drive the expression of UAS-RasV12.  The fly stock and cells also 
had an attP flanked genomic cassette, a target for Recombination Mediated Cassette Exchange, 
which can be used to later insert transgenes of interest into the cells (Manivannan et al. 2015).  
Eight primary cultures were made and seven were passaged at least once.   Just like the repo-
Gal4; UAS-Ras
V12,  UAS-GFP cells, no cell lines were generated from this cross, leading to our 
belief that RasV12 expression alone would not lead to a glial-specific cell line (Figure 3).  In other 
animal models, such as in the mouse, expression of RasV12 in cell culture leads to premature 
senescence unless another oncogene is involved or a tumor suppressor is inactivated (Serrano et 
al. 1997). 
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Figure 2: repo-Gal4 ; UAS-Ras
V12
,UAS-GFP primary culture.  GFP expression present in 
cells expressing repo, glial cells..  A,B: Phase and GFP image of a primary culture at day 2.  
Different cell types are present in the primary culture.  Cells marked by GFP are glial.  C,D: 
Phase and GFP images of a primary culture at day 12.  There are proliferating patches in 
culture. E,F:  Phase and GFP images of a primary culture at day 14.  The cell culture flask is 
confluent with cells expressing GFP, glial cells. 
A 
C 
E 
B 
D 
F 
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Establishment of a glial-specific cell line 
Based on the expression of UAS-RasV12 ,UAS-GFP, we decided that repo-Gal4 was a 
good pan-glial driver, but we would need to utilize a different responder line to generate the cell 
line, we could not utilize expression of RasV12 alone.  We crossed the repo-Gal4 stock with a 
variety of other responder lines.  Included in this list is UAS- wtsdsRNA , UAS-RasV12 ;UAS-wts 
dsRNA, UAS-P35, UAS-RasV12, and tub-Gal80; UAS-RasV12.   
 
repo-Gal4; UAS-wtsdsRNA 
Repo-Gal4 was used to drive the expression of wtsdsRNA in culture.  wts is a known 
Drosophila tumor suppressor (Justice et al. 1995), so knocking down the expression of wts in 
glial cells could lead to the proliferation of glial cells in culture.  Out of five repo-Gal4 ; UAS-
wtsdsRNA primaries, two primary cultures led to lines.  These lines, however, stained negative for 
repo, indicating that they were not glial in nature (Figure 4).   
 
 
Figure 3: repo-Gal4; UAS-Ras
V12;  RMCE cells.  The primary culture became confluent and 
was passaged on day 19.  Cells in later passages are unhealthy and do not reach confluence 
before dying and lifting off the plate. 
Primary P2 Primary 
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repo-Gal4; UAS-RasV12; UAS-wtsdsRNA  
I next tested UAS-RasV12 in combination with UAS-wts dsRNA to test whether they would 
increase the likelihood of glial cell proliferation in culture. None of the five primaries of repo-
Gal4; UAS-RasV12 ; UAS-wtsdsRNAled to cell lines; the cells in the primary culture grew very 
quickly and appeared unhealthy in later passages, leading to death (Figure 5).   
 
 
 
 
repo DAPI 
Primary P17 
Figure 4: repo-Gal4; UAS-wts dsRNA cell line.  A cell line was developed using repo-Gal4 
and UAS-wts dsRNA.  Top left: Primary culture at 26 days.  Top right: Passage 17 of the cell 
line.  Bottom left: Cell line is stained with anti-repo antibody and the result is negative.  
Bottom right: DAPI staining illustrates the presence of cells in the field of view. 
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repo-Gal4; UAS-P35, UAS RasV12 
Next, to determine if blocking cell death would generate glial-specific cell lines, I crossed 
repo-Gal4 to UAS-P35, UAS-RasV12.  P35 is a protein that blocks cell death, including cells in 
developing embryos (Hay, Wolff, and Rubin 1994). From six primaries, no cell lines were 
developed.  On average, at passage 3, the cells began to look unhealthy, lifting off of the flask 
surface before reaching confluency (Figure 6).  In addition, UAS-P35, UAS RasV12 flies with an 
RMCE site were crossed with repo-Gal4 and the results were similar to the results of the cross 
with no RMCE site, as expected, because the RMCE site is a “neutral” element for future 
transgene insertion.  A summary of the primary cultures resulting from the cross is in Table 1. 
 
 
 
 
 
 
 
Figure 5: repo-Gal4; UAS-Ras
V12
; UAS-wtsdsRNA cells.  Cells were confluent and passaged 
after 13 days.  left: primary culture.  right: cells were dying and lifting off the plate in 
passage 2. 
P2 Primary 
Primary P3 
Figure 6: repo-Gal4; UAS-P35, UAS-Ras
V12 
 cells.  Cells were confluent and passaged after 
22 days.  left: primary culture.  right: cells were unhealthy and dying in passage 3. 
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tub-Gal80ts; repo-Gal4; UAS-RasV12 
 Reducing RasV12 expression proved to be key for continued growth. I successfully 
derived a cell line by controlling the level of expression of RasV12 using the temperature sensitive 
Gal4 inhibitor, Gal80  (Suster et al. 2004).  At lower temperatures, Gal80 reduces the expression 
of RasV12  by repressing Gal4 in some cells (Suster et al. 2004).  Primaries of  tub-Gal80ts; repo-
Gal4; UAS-RasV12 were plated.  From six primary cultures, one line was developed termed 
RepoG80-6.  The passages of this line were grown at three different temperatures: 25℃, 22℃, 
and 18℃ and in different conditions of medium: Schneider’s Insect Media, 10%FBS (Fetal 
Bovine Serum) and Penicillin-Streptomycin with and without 10-20% pyruvate and Schneider’s 
Insect Media, 10%FBS. The line grew the most successfully at 18℃ in Schneider’s Insect Media 
supplemented only with FBS, when RasV12 expression was at its lowest.  As seen in Figure 7, 
RepoG806 has been passaged over ten times, indicating it is a cell line. 
 
 
 
 
 
 
 
 
 
 
Figure 7: tub-Gal80TS; repo-Gal4; UAS-Ras
V12
 cells.  Cells were confluent and passaged 
after 26 days.  left: primary culture.  right: cells as a line at passage 13. 
Primary P13 
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A summary of reporter lines crossed with repo-Gal4, number of primaries, and cell lines 
generated is shown in Table 1.  Figure 8 shows growth charts for each set of primaries, organized 
by responder line. 
repo-Gal4 > 
(glial-specific 
driver) 
UAS-
Ras
V12
 
(+/- attP*) 
UAS-wts 
dsRNA
 
UAS-
Ras
V12 
; 
UAS-wts 
dsRNA
  
UAS-
P35, 
UAS-
Ras
V12
 
(+/- attP*) 
Tub-
Gal80TS; 
UAS-
Ras
V12
  
Number of primary 
cultures 
6 5 5 10 6 
Days to confluence 22 42 16 21 34 
Number of cell lines 
developed 
0 0 0 0 1 
 
 
 
  
 
 
 
 
  
  
Table 1: Summary of primary cultures and resulting cell line.  Only tub-Gal80TS; repo-Gal4; UAS-Ras
V12
 developed 
into a line. *attP is an insertion site for transgenes using RMCE 
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Figure 8: Cell culture passage charts illustrating the number of days between passages. Notably, 
the days between passages of repo-Gal4; UAS-RasV12 ; UAS-wtsdsRNA are significantly shorter than 
the other cultures.  Only tub-Gal80TS; repo-Gal4; UAS-Ras
V12
 developed into a line, the only cell 
culture that was passaged over ten times besides the repowts15, which stained negative for repo, and 
is not glial in nature. Note: The vertical axis of the repo-Gal4 > UAS wtsdsRNA growth chart is scaled 
differently from the other graphs.  
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Characterization of RepoG80-6 
 To determine if RepoG80-6 had characteristics of glial cells, I tested for expression of 
repo using anti-repo antibody  (Alfonso and Jones 2002) and a variety of neuronal markers.  
22C10 is an antibody that recognizes Futsch, a protein necessary for dendritic and axonal growth 
(Fujita et al. 1982; Hummel et al. 2000).   Antibodies that are specific to HRP bind to neuronal 
membranes, inducing membranes of  sensory and peripheral nerves, and serve as a neuronal 
marker (Jan and Jan 1982). Anti-Fas II antibodies also are specific to neuronal cells.  Fas II is a 
protein that is responsible for the adherence of growing axons to one another and for the process 
of presynaptic phenotypic plasticity (García-Alonso et al. 1995).  The results of the staining 
experiments are shown in Figure  9.  RepoG80-6 expressed repo and a small fraction of cells 
expressed Fas II; most cells are glial in nature, but there may be other cell types present in the 
culture.  The existence of cells expressing Fas II may indicate the presence of motor neurons, but 
some studies speculate that anti-FasII antibodies may stain cells that are glial in nature (Hebbar 
and Fernandes 2005).  Because the RepoG80-6 cells were negative for anti-HRP and 22C10, 
other pan-neuronal antibodies, it is plausible that FasII is expressed in cells other than neurons, 
such as a small subset of glial cells.   
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Figure 9: Immunostaining of RepoG80-6.  RepoG80-6 expresses repo (A) but not 22C10 (B), HRP (C).  Some 
cells express Fas II (D).  E depicts a control in which no primary antibody was added.  F shows repo antibody 
staining of an epithelial line. 
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Karyotype analysis was conducted on RepoG80-6 and the results are shown in Figure 10.  
Similar to RepoG80-6, human glioblastoma cell cultures sometimes exhibit an extra number of 
chromosomes (Westphal et al. 1994). 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Karyotype of repo G80 6 cell line. A,B: Examples of karyotypes found in the RepoG80-6 cell line. 
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Appearance of another cell type in the RepoG80-6 cell line 
 After approximately 20 passages, the morphology of the RepoG80-6 cells began to 
change (Figure 11).  Cells appeared to be smaller, with shorter projections (Figure 11). After 
staining later passages of RepoG806, it was found that the cells were no longer expressing repo 
and were expressing Fas II, indicating that the cell type was most likely neuronal in nature 
(Figure 12).  An earlier passage of RepoG80-6 was then thawed and used, which consisted of the 
glial cell-type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11:  Morphological changes in RG80-6 line. A: RG80-6 no longer had the 
same morphology at a later passage.  B: RG80-6 glial cell-type morphology. 
 
A B 
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A
A 
Figure 12:  Immunostaining confirms that the cells of RepoG806 changed in 
morphology and cell type.  Cells no longer expressed repo (A).  The cells still did 
not express 22C10 (B) or HRP (C).  They were found to express Fas II (D).  The cells 
proliferating in the culture may be a subset of neuronal cells.  No primary antibody 
was added in the control (E). 
B 
C D 
E 
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Conclusion 
 Because there is a low recovery of glial-specific cell lines, additional spontaneous genetic 
changes that combine with (or modify) RasV12 expression are likely to be required for glial-
specific cell line generation.  Despite these genetic changes, the line that I developed is a useful 
tool that can be used to study glial cells and glial diseases in Drosophila and mammals.   
  
FUTURE DIRECTIONS 
Using repo-Gal4 as a driver for other tumor suppressor knockdowns in combination with 
RasV12 expression 
The tumor suppressor brat is important in the Drosophila brain, promoting asymmetric 
cell division and directing neural differentiation. brat loss of function results in a massively 
enlarged brain (Chen et al. 2014).  TRIM3, the human ortholog of brat, also regulates 
asymmetric cell division. In humans, TRIM3 expression is reduced in samples of glioblastoma 
(Chen et al. 2014). To gain insights into the functions of TRIM3 in GBM, I utilized the RNAi 
knockdown of brat to develop a cell line to model GBM.  Repo-Gal4; UAS bratdsRNA primary 
cultures have been generated, and more cultures are currently in progress.   
 I have also developed a fly line that contains transgenes encoding both brat dsRNA and 
RasV12.  The generation of the stock is shown in Figure 13.  The primary cultures are currently 
being generated. 
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        w+/; +/+; bratdsRNA/ bratdsRNA        X       w-/w-; sp/CyO; L/Tm6,Tb      X w-/w-; RasV12/RasV12; +/+ 
 
 
                                       w-; +/CyO; bratdsRNA/L          X           w-; RasV12/ CyO; +/Tm6 
 
 
       w-; RasV12/CyO; bratdsRNA/Tm6 
 
 
Using other glial-specific drivers to generate cell lines 
 I will use Gal4 drivers for more specific subtypes of glial cells, like the astrocyte, to 
develop more specific cell lines.  To develop an astrocyte-specific fly cell line, I will use alrm 
(astrocytic leucine-rich repeat molecule)-Gal4, a Gal4 driver line expressed only in astrocytes in 
the antennal lobe of Drosophila (Freeman 2015).  By crossing an alrm-Gal4 line with the set of 
responder lines that I have discussed above, I will be able to generate an astrocyte-specific cell 
line.  Primary cultures of alrm-Gal4; UAS-RasV12 RMCE have been established (Figure 14) and 
are being processed. 
 
 
   
 
 
  
 
 
 
Figure 13:  Generation of UAS-RasV12; UAS-bratdsRNA stock. 
A-Primary B-Primary 
Figure 14: alrm-Gal4 > UAS-RasV12 RMCE.  Primary cultures on (A) day 10 and (B) day 
39.  
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Further characterization and maintenence of RepoG80-6 
 I will further characterize the glial-specific cell lines by doing more extensive antibody 
stains.  I will stain for a variety of glial cell markers in RepoG80-6 to find the subtype of glial 
cells proliferating in culture.   
 To maintain the RepoG80-6 cell line, I have frozen cells at different passage numbers 
before the appearance of another cell type.  These frozen cells can be thawed and used for further 
characterization and experiments.  Once thawed, another cell type may appear in later passages.  
It is important that I freeze cells at earlier passages so that there is a supply of RepoG80-6 glial 
cells.  To purify the glial cell line, I am considering cloning cells from a culture of RepoG80-6.  
Clonal lines are typically more homogenous, so other cell types may not appear (Cherbas and 
Gong 2014). 
 
RNA Sequencing of RepoG806 
RNA sequencing could reveal the gene expression of the cells and highlight certain genes 
or pathways that may have an important role in the growth of a brain tumor in Drosophila. These 
genes or pathways may have a mammalian equivalent that plays an important role in 
glioblastoma formation. 
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